DYSPAREUNIA TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Dyspareunia Treatment Market, By Drug Type (Selective Estrogen Receptor Modulators, Estrogens (Miscellaneous Vaginal Agents), Corticosteroids, Antibiotics, and Others), By Route of Administration (Oral, Vaginal Inserts, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E-commerce, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Apr 2024
Code : CMI6885
Pages :168
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Dyspareunia Treatment Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increasing Product Launches by Key Market Players

Increasing adoption of organic growth strategies, such as product launches, by key market players for the treatment of dyspareunia are expected to drive the market growth over the forecast period. For instance, in February 2022, Duchesnay Inc., a global pharmaceutical company, announced that it had launched Osphena (ospemifene tablets), a Selective Estrogen Receptor Modulator (SERM) in Canada for the treatment of vaginal dryness and dyspareunia. Osphena has been shown in phase II and III clinical studies to treat moderate to severe dyspareunia (painful intercourse) and/or vaginal dryness in postmenopausal women, which are symptoms of vulvar and vaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).

Key Players Insights